Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antibacterial
    (1)
  • Antibiotic
    (1)
  • Endogenous Metabolite
    (1)
  • STING
    (1)
  • Others
    (2)
TargetMol | Tags By ResearchField
  • Immune System
    (2)
  • Infection
    (2)
  • Inflammation
    (2)
  • Metabolism
    (1)
  • Nervous System
    (1)
  • Respiratory System
    (1)
Filter
Search Result
Results for "

T8390

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    4
    TargetMol | All_Pathways
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Natural Products
    1
    TargetMol | Natural_Products
Cefazolin
T839025953-19-9
Cefazolin is a semi-synthetic cephalosporin that has a broad spectrum of antibacterial activity and inhibits the synthesis of bacterial cell walls.
  • $35
In Stock
Size
QTY
12β-Hydroxyisocholic Acid
LCA, Lagocholic Acid
T8390071883-64-2
12β-Hydroxyisocholic Acid (Lagocholic Acid) is a bile acid isomer that has been implicated in bile metabolism and may be used in the study of metabolic disorders.
  • $40
In Stock
Size
QTY
BDW568
T83901335401-44-0
BDW568, a prodrug of BDW-OH, serves as a stimulator of interferon genes (STING) agonist. This compound effectively induces STING transcriptional activity, evidenced by a reporter assay in THP-1 cells, with an EC50 value of 7.6 µM. Furthermore, at a concentration of 50 µM, BDW568 prompts phosphorylation of TANK-binding kinase 1 (TBK1) and IFN regulatory factor 3 (IRF3) within THP-1 cells, showcasing its biochemical activity in cellular signaling pathways.
  • $213
35 days
Size
QTY
Tirzepatide sodium
LY3298176
T83906
Tirzepatide acts as an agonist for both the glucagon-like peptide 1 receptor (GLP-1R) and G protein-coupled receptor 119 (GPR119), effectively inducing cAMP production in HEK293 cells that express either human GLP-1R or GPR119, with EC50 values of 6.54 and 1.01 nM, respectively. Additionally, at a concentration of 100 nM, it triggers receptor internalization in these cells. In vivo studies demonstrate that tirzepatide, administered at 10 nmol/kg per day, significantly reduces body weight, food intake, as well as plasma and hepatic triglyceride levels, free fatty acids (FFAs), leptin, and blood glucose in mice with high-fat diet-induced obesity. Furthermore, a dose of 50 nmol/kg every three days prevents an increase in eosinophils and lymphocytes in the bronchoalveolar lavage fluid (BALF) and inhibits bronchoconstriction prompted by methacholine in mice models of both asthma and diabetes, indicating its potential in treating type 2 diabetes mellitus.
  • $265
In Stock
Size
QTY